Accelerate to discover
Related topics
NovoCyte Quanteon webinar: In-depth cell Proliferation through new advances in flow cytometry
Dec 11, 2018
Cell proliferation is one of the most fundamental biological processes in biology. Many of the traditional assays to...
Webinar: early detection of metabolic remodeling in pressure overload left ventricle Hypertrophy
Nov 28, 2018
Do you already heard the hypothesis that metabolic changes in the heart may precede and even trigger structural and...
Xcell Bio webinar: AVATAR system, to control cell state to get better cells, fast
Oct 30, 2018
Dr. Schneider will show examples of data from customers who have incorporated pressure along with oxygen to recreate...
Understanding subtle cardiac changes
Oct 3, 2018
Are you working with high ultrasound imaging and are you interesting in VevoStrain application and specific changes in...
Contrast-enhanced ultrasound imaging
Sep 5, 2018
Are you interested in photoacoustic imaging and would like to enhance your contrast imaging acquisitions? Just use...
Aug 9, 2018
We bring you the latest KOL interview on the Albira Si PET/SPECT/CT from Prof. John Prior, CHUV Lausanne. He describes...
Webinar Tuning Microenvironment to Control Cells for Improved Disease Modeling & Immunotherapy Work
Jul 16, 2018
The company producing Avatar, xCELL biosciences have organized a webinar about the tuning of microenvironment to...
How microCT can provide insight into dynamic disease processes webinar
Jun 19, 2018
Professor Vande Velde will describe how high-field MRI and low dose microCT complement each other; where microCT gives...
Nov 22, 2018
Researchers developed an assay to measure CLL cell interactions with endothelium under shear force using a Bioflux 200 and blocked CD62L using the anti-CD62L antibody DREG-56. CLL cell interactions with endothelium were visualized by time-lapse microscopy and CLL cell movement was tracked and quantified. Data will be discussed in the webinar and will establish targeting CD62L inhibits CLL cell/endothelial cell interactions and is accentuated by co-administration with ibrutinib. These data imply that some of the clinical effects caused by ibrutinib are due to a reduced capacity of CLL cells to engage endothelium and extravasate.
Dr. Chris Pepper, Professor in Cancer Studies, University of Sussex, UK
Related technologies: Cell interaction studies
Get more info
Brand profile
With BioFlux System for live cell analysis under shear flow and IsoFlux System for circulating tumor cell analysis, Fluxion Biosciences turn power of benchtop cellular analysis with advanced tools to automate complex assays.
More info at:
www.fluxionbio.com
BioFocus newsletter
Register to receive Brand new technology development, Important product updates, Interesting scientific events and more!
BioTech a.s. © 2014
Designed & developed by imagineit
Technologies
